Antitumoral and Antimetastatic effects of guluronate in murin breast cancer model

اولين كنگره بين المللي تازه هاي پيشگيري، تشخيصي و درماني سرطان پستان

18 الي 20 آبان 1395، تبريز - ايران

Presentation Type: Poster
Abstract: Introduction:Today, malignancies and cancer, are the most common causes of death in human societies. According to published statistics, the United States of America accounted for more than 25 percent of cancer deaths, the most important cause of death. Common current treatment for cancer include chemotherapy, radiotherapy and surgery are cancerous tissue. especially devastating side effects on healthy cells, on the other hand, is always a serious problem in the way of this treatment have been raised. Breast cancer in the world after lung and stomach cancer, the second most common cancer. Despite significant advances in both diagnosis and treatment of cancer occurring, but metastasis is responsible for over 90% of deaths associated with cancer. Given the proven role of chronic inflammation in the development and progression of cancer, anti-inflammatory treatments as targets in cancer patients has always been to improve the situation. Nonsteroidal anti-inflammatory drugs (NSAIDs) use in cancer treatment due to adverse reactions in different organs (these effects mainly gastrointestinal system, blood vessels are associated), in practice with restrictions are facing. For this reason, the need to develop drugs with fewer side effects, cancer patients should be considered to improve more. Due to the extremely low toxicity of new anti-inflammatory drug Guluronate G2013, and due to all the negative use of NSAIDs available, assess the anti-inflammatory effects of the drug and the reduction or treatment of breast cancer, it is very important to reach. As mentioned above, inflammation and inflammatory pathways, involved in cancer and cause severe complications that lead to malignancies.
Results: Our survey showed that Guluronate, could have anti-inflammatory effects on the reduction of inflammatory cytokines including IL-6, IL-1β and TNF-α and reduced levels of expression and activity of MMP2 / 9 and decreased expression levels of inflammatory enzymes cyclooxygenase -2 (COX-2), inhibiting the progression of breast cancer.